-
公开(公告)号：US20200040089A1
公开(公告)日：2020-02-06
申请号：US16527354
申请日：2019-07-31
Applicant: Cephalon, Inc.
Inventor： Doris Shim Siew Chen , Lynn Dorothy Poulton , Adam Clarke , David Jose Simon Laine , Matthew Pollard , Bridget Ann Cooksey , Anthony Doyle , Jason William Gill
Abstract: Disclosed herein are human antibody molecules that immunospecifically bind to human CXCR2. The disclosed human antibody molecules are potent and selective antagonists of CXCR2 functions and prevent the recruitment of neutrophils into tissues without strongly depleting circulating neutrophil numbers. Pharmaceutical compositions, nucleic acid molecules, vectors, cells, and uses of the disclosed antibodies are also provided.
-
公开(公告)号：US20170081400A1
公开(公告)日：2017-03-23
申请号：US15267213
申请日：2016-09-16
Applicant: Cephalon, Inc.
Inventor： Lynn Dorothy Poulton , Matthew Pollard , Anthony G. Doyle , Bridget Ann Cooksey , Vanya Pande , Adam William Clarke
IPC: C07K16/24
CPC classification number: C07K16/241 , A61K2039/505 , A61P11/06 , A61P37/06 , C07K16/2875 , C07K2317/21 , C07K2317/33 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: Recombinantly expressed variant antibodies that have enhanced affinity for TL1A and enhanced potency relative to the parent antibody from which they were derived are provided. The antibodies inhibit the interaction between TL1A and the death receptor 3 (DR3). The antibodies, or a composition thereof, may be used to treat one or more of asthma, COPD, pulmonary fibrosis, cystic fibrosis, inflammatory bowel disease, a gastrointestinal disease associated with cystic fibrosis, Crohn's disease, colitis, ulcerative colitis, irritable bowel syndrome, eosinophilic esophagitis, atopic dermatitis, eczema, scleroderma, arthritis, or rheumatoid arthritis.
-
公开(公告)号：US20190106486A1
公开(公告)日：2019-04-11
申请号：US16164509
申请日：2018-10-18
Applicant: Cephalon, Inc.
Inventor： Lynn Dorothy Poulton , Matthew Pollard , Anthony G. Doyle , Bridget Ann Cooksey , Vanya Pande , Adam William Clarke
Abstract: Recombinantly expressed variant antibodies that have enhanced affinity for TL1A and enhanced potency relative to the parent antibody from which they were derived are provided. The antibodies inhibit the interaction between TL1A and the death receptor 3 (DR3). The antibodies, or a composition thereof, may be used to treat one or more of asthma, COPD, pulmonary fibrosis, cystic fibrosis, inflammatory bowel disease, a gastrointestinal disease associated with cystic fibrosis, Crohn's disease, colitis, ulcerative colitis, irritable bowel syndrome, eosinophilic esophagitis, atopic dermatitis, eczema, scleroderma, arthritis, or rheumatoid arthritis.
-
Patent Agency Ranking
公开(公告)号：US11332534B2
公开(公告)日：2022-05-17
申请号：US16527354
申请日：2019-07-31
Applicant: Cephalon, Inc.
Inventor： Doris Shim Siew Chen , Lynn Dorothy Poulton , Adam Clarke , David Jose Simon Laine , Matthew Pollard , Bridget Ann Cooksey , Anthony Doyle , Jason William Gill
Abstract: Disclosed herein are human antibody molecules that immunospecifically bind to human CXCR2. The disclosed human antibody molecules are potent and selective antagonists of CXCR2 functions and prevent the recruitment of neutrophils into tissues without strongly depleting circulating neutrophil numbers. Pharmaceutical compositions, nucleic acid molecules, vectors, cells, and uses of the disclosed antibodies are also provided.
-
公开(公告)号：US11267883B2
公开(公告)日：2022-03-08
申请号：US16471616
申请日：2017-12-21
Applicant: Cephalon, Inc.
Inventor： David Jose Simon Laine , Matthew Pollard , Anthony Gerard Doyle , Lynn Dorothy Poulton , Adam William Clarke
Abstract: Recombinant antibodies that specifically bind to IL-15 as well as a complex of IL-15 and the IL-15 Receptor-alpha are provided. The antibodies inhibit immune cell proliferation, and are capable of use in the treatment of any autoimmune or inflammatory disease or condition where IL-15 is dysregulated, including Celiac disease.
-
6.发明授权公开(公告)号：US11220549B2
公开(公告)日：2022-01-11
申请号：US16164509
申请日：2018-10-18
Applicant: Cephalon, Inc.
Inventor： Lynn Dorothy Poulton , Matthew Pollard , Anthony G. Doyle , Bridget A. Cooksey , Vanya Pande , Adam W. Clarke
Abstract: Recombinantly expressed variant antibodies that have enhanced affinity for TL1A and enhanced potency relative to the parent antibody from which they were derived are provided. The antibodies inhibit the interaction between TL1A and the death receptor 3 (DR3). The antibodies, or a composition thereof, may be used to treat one or more of asthma, COPD, pulmonary fibrosis, cystic fibrosis, inflammatory bowel disease, a gastrointestinal disease associated with cystic fibrosis, Crohn's disease, colitis, ulcerative colitis, irritable bowel syndrome, eosinophilic esophagitis, atopic dermatitis, eczema, scleroderma, arthritis, or rheumatoid arthritis.
-
公开(公告)号：US10138296B2
公开(公告)日：2018-11-27
申请号：US15267213
申请日：2016-09-16
Applicant: Cephalon, Inc.
Inventor： Lynn Dorothy Poulton , Matthew Pollard , Anthony G. Doyle , Bridget Ann Cooksey , Vanya Pande , Adam William Clarke
IPC: C07K16/24 , C12N5/10 , C12N15/10 , C12N15/13 , C12N15/63 , G01N33/53 , C07K16/28 , A61P37/06 , A61P11/06 , A61K39/00
Abstract: Recombinantly expressed variant antibodies that have enhanced affinity for TL1A and enhanced potency relative to the parent antibody from which they were derived are provided. The antibodies inhibit the interaction between TL1A and the death receptor 3 (DR3). The antibodies, or a composition thereof, may be used to treat one or more of asthma, COPD, pulmonary fibrosis, cystic fibrosis, inflammatory bowel disease, a gastrointestinal disease associated with cystic fibrosis, Crohn's disease, colitis, ulcerative colitis, irritable bowel syndrome, eosinophilic esophagitis, atopic dermatitis, eczema, scleroderma, arthritis, or rheumatoid arthritis.
-
公开(公告)号：US20220348671A1
公开(公告)日：2022-11-03
申请号：US17718622
申请日：2022-04-12
Applicant: Cephalon, Inc.
Inventor： Doris Shim Siew Chen , Lynn Dorothy Poulton , Adam Clarke , David Jose Simon Laine , Matthew Pollard , Bridget Ann Cooksey , Anthony Doyle , Jason William Gill
Abstract: Disclosed herein are human antibody molecules that immunospecifically bind to human CXCR2. The disclosed human antibody molecules are potent and selective antagonists of CXCR2 functions and prevent the recruitment of neutrophils into tissues without strongly depleting circulating neutrophil numbers. Pharmaceutical compositions, nucleic acid molecules, vectors, cells, and uses of the disclosed antibodies are also provided.
-
-
-
-
-
-
-
Search Results
8
records
(took 0.023 seconds)
